Loading stock data…
$13.11-0.25 (-1.87%)
AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom.
AVITA Medical, Inc. in the Healthcare sector is trading at $12.94 with a market capitalization of $400M. Wall Street consensus targets $13.44 (3 analysts), implying a +3.8% move over the next 12 months. The stock is currently near its 52-week high of $13.73, remaining 120.8% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $21.70M↑ | $19.25M↑ | $17.61M↑ | $17.06M↓ | $18.42M |
| Gross Profit | $17.77M↑ | $15.73M↑ | $14.31M↑ | $13.88M↓ | $14.95M |
| Operating Income | -$6.86M↑ | -$8.80M↑ | -$10.41M↓ | -$9.15M↑ | -$11.15M |
| Net Income | -$7.66M↑ | -$10.61M↑ | -$11.62M↑ | -$13.19M↓ | -$9.92M |
AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company's lead product is the RECELL System, a cell harves...